TScan Therapeutics Statistics Share Statistics TScan Therapeutics has 56.59M
shares outstanding. The number of shares has increased by 6.83%
in one year.
Shares Outstanding 56.59M Shares Change (YoY) 6.83% Shares Change (QoQ) 0% Owned by Institutions (%) 29.89% Shares Floating 49.66M Failed to Deliver (FTD) Shares 6,227 FTD / Avg. Volume 1.08%
Short Selling Information The latest short interest is 1.83M, so 3.24% of the outstanding
shares have been sold short.
Short Interest 1.83M Short % of Shares Out 3.24% Short % of Float 3.94% Short Ratio (days to cover) 5.6
Valuation Ratios The PE ratio is -2.67 and the forward
PE ratio is -1.39.
TScan Therapeutics's PEG ratio is
0.17.
PE Ratio -2.67 Forward PE -1.39 PS Ratio 120.9 Forward PS 11.4 PB Ratio 1.41 P/FCF Ratio -2.97 PEG Ratio 0.17
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for TScan Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.14,
with a Debt / Equity ratio of 0.4.
Current Ratio 8.14 Quick Ratio 8.14 Debt / Equity 0.4 Debt / EBITDA -0.81 Debt / FCF -0.85 Interest Coverage -36.91
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $14.08K Profits Per Employee $-637.5K Employee Count 200 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -73.33% in the
last 52 weeks. The beta is 0.99, so TScan Therapeutics's
price volatility has been higher than the market average.
Beta 0.99 52-Week Price Change -73.33% 50-Day Moving Average 1.67 200-Day Moving Average 2.41 Relative Strength Index (RSI) 44.49 Average Volume (20 Days) 576,372
Income Statement In the last 12 months, TScan Therapeutics had revenue of 2.82M
and earned -127.5M
in profits. Earnings per share was -1.14.
Revenue 2.82M Gross Profit 2.82M Operating Income -134.82M Net Income -127.5M EBITDA -119.74M EBIT -123.85M Earnings Per Share (EPS) -1.14
Full Income Statement Balance Sheet The company has 178.69M in cash and 97.38M in
debt, giving a net cash position of 81.31M.
Cash & Cash Equivalents 178.69M Total Debt 97.38M Net Cash 81.31M Retained Earnings -375.1M Total Assets 332.71M Working Capital 225.02M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -110.82M
and capital expenditures -3.83M, giving a free cash flow of -114.65M.
Operating Cash Flow -110.82M Capital Expenditures -3.83M Free Cash Flow -114.65M FCF Per Share -1.02
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -4787.68% and -4527.66%.
Gross Margin 100% Operating Margin -4787.68% Pretax Margin -4527.66% Profit Margin -4527.66% EBITDA Margin -4252.06% EBIT Margin -4787.68% FCF Margin -4071.27%
